Clinical Trials Logo

Subarachnoid Hemorrhage clinical trials

View clinical trials related to Subarachnoid Hemorrhage.

Filter by:

NCT ID: NCT05851989 Recruiting - Clinical trials for Aneurysmal Subarachnoid Hemorrhage

Study on Prognosis of Acutely Ruptured Intracranial Aneurysms

SPARTA
Start date: July 14, 2021
Phase:
Study type: Observational

The SPARTA study is a prospective multicenter observational trial in the Netherlands with the aim of identifying the best clinical care in patients with aneurysmal subarachnoidal haemorrhage. Differences in outcome between surgical treatment and endovascular treatment will be explored. Furthermore, cost effectiveness and radiological prognostic factors will be examined.

NCT ID: NCT05818371 Not yet recruiting - Clinical trials for Subarachnoid Hemorrhage

Non-invasive ONSD-based Neuromonitoring in a Neurointensive Care Setting

ONSDDynamics
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Intensive care patients with established invasive intracranial neuromonitoring due to neurotrauma are subjected to a repeated non-invasive sonographic recording of the optic-nerve-sheath-diameter (ONSD). The recorded images are analyzed through a machine-learning-algorithm and an experienced ultrasound operator. Results are correlated to the parallel recorded intracranial pressure (ICP). The study aims to establish ONSD as a supplementary for raised ICP.

NCT ID: NCT05777499 Not yet recruiting - Stroke Clinical Trials

MUSic Therapy In Complex Specialist Neurorehabilitation

MUSICS
Start date: March 2023
Phase: N/A
Study type: Interventional

Aim: Investigate whether patients undergoing specialist rehabilitation after complex neurological injury show different functional outcomes if music therapy is included in their rehabilitation program compared to usual care. Background: Patients with complex needs following a brain, spinal cord, and/or peripheral nerve injury often require a period of specialist neurorehabilitation. This involves multiple therapy disciplines, led by a Consultant in Rehabilitation Medicine, Neurology, or Neuropsychiatry. Although music therapy is suggested to enhance neuroplasticity and recovery in patients with brain injury, it is not routinely commissioned in clinical care due to a lack of supportive evidence. Hypothesis: Patients undergoing music therapy in addition to complex specialist rehabilitation show better functional outcomes compared to usual care. Number of participants: 75, aged 16-80 years. Methods: Patients undergo baseline assessments and are randomised to MUSIC or CONTROL Therapy. Both arms receive 1-3 additional therapy sessions per week, matched for duration and number, total 15 hours. After approximately 10-weeks intervention, assessments are repeated. All participants then have access to music therapy until they are discharged from Neurorehabilitation Unit (NRU), with additional qualitative data collection using semi-structured interviews, field notes, staff reports, staff stress surveys, and broader ecological observations. Duration for Participants: From consent to discharge from NRU. Primary Outcome: Change in Functional Independence Measure+Functional Assessment Measure (FIM+FAM), Northwick Park Dependency Scale (NWPDS), and Barthel Activities of Daily Living pre and post 15 hours intervention. Secondary Outcome: Change in quality of life (Flourishing Scale), psychological distress (Hospital Anxiety and Depression Scale, Depression Intensity Scale Circles), social interaction (Sickness Impact Profile Social Interaction Subscale), well-being (WHO Well-Being Index), and communication (Communication Outcomes After Stroke Scale), pre and post 15 hours intervention. Mean difference in well-being (WHO Well-Being Index) throughout the intervention period between music therapy and control therapy groups. Mean difference in post-intervention pain and mood visual analogue scores between music therapy and control therapy groups.

NCT ID: NCT05738083 Active, not recruiting - Clinical trials for Aneurysmal Subarachnoid Hemorrhage

Prediction Models for Complications, Disability, and Death in Patients With Aneurysmal Subarachnoid Hemorrhage

Start date: October 1, 2018
Phase:
Study type: Observational [Patient Registry]

This study aims to prospectively collect the clinical and radiogical features to investigate the associations between the potential risk factors and secondary complications, adverse long-term functional outcomes, and death in patients with aneurysmal subarachnoid haemorrhage (aSAH).

NCT ID: NCT05727657 Not yet recruiting - Clinical trials for Aneurysmal Subarachnoid Hemorrhage

Satralizumab in Aneurysmal Subarachnoid Hemorrhage

SASH
Start date: July 1, 2024
Phase: Early Phase 1
Study type: Interventional

In this study, satralizumab will be administered to see whether satralizumab is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.

NCT ID: NCT05714735 Active, not recruiting - Arterial Aneurysm Clinical Trials

SMCV Assessment on Brain Swelling in Patients With SAH From Ruptured Artery Aneurysm

SMCV
Start date: November 1, 2017
Phase:
Study type: Observational [Patient Registry]

Superficial cerebral veins findings in assessment of brain swelling in patients with aneurysmal subarachnoid hemorrhage who underwent intravenenous DSA examinations

NCT ID: NCT05696639 Active, not recruiting - Clinical trials for Subarachnoid Hemorrhage

SMCV Assessment on Brain Swelling in Patients With SAH

Bayysmcv
Start date: April 1, 2017
Phase:
Study type: Observational

Cerebral swelling is a major complication following aneurysmal subarachnoid hemorrhage.This study is a retrospective cohort aimed to predict the extent of brain swelling. Cerebral venous assessment can identify the risk of brain swelling and improve surgical outcomes.

NCT ID: NCT05686265 Terminated - Clinical trials for Subarachnoid Hemorrhage, Aneurysmal

Cerebral Nitrosative/Oxidative Stress in Aneurysmal Subarachnoid Haemorrhage

NOX2
Start date: May 11, 2023
Phase:
Study type: Observational

Aneurysmal subarachnoid haemorrhage (SAH) carries a high morbidity and mortality, which is in part due to the development of secondary brain injury. The mechanisms behind this remain incompletely understood, but oxidative/nitrosative stress and disturbances in vasoregulatory mechanisms are believed to be involved. The present study aims to characterise the transcerebral exchange of oxidative/nitrosative stress markers and nitric oxide metabolites during the early phase after SAH compared to healthy volunteers, including the influence of induced changes in arteriel oxygen tension.

NCT ID: NCT05664191 Recruiting - Clinical trials for Sub-arachnoid Haemorrhage

Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage

LEVOSAH
Start date: October 13, 2023
Phase: Phase 2
Study type: Interventional

Sub-arachnoid haemorrhage (SAH) are often due to ruptured intracerebral aneurysms and are associated with an importante morbi-mortality. SAH are often complicated by delayed cerebral ischemia (DCI) potentially due to cerebral vasospasm (CVS). A recent study showed that levosimendan, an inotropic and vasodilatory drug, could reduce the incidence of CVS and potentially improve patient outcome. In this pilot randomized controlled trial, we will evaluate the impact Levosimendan vs Placebo in SAH patient on the occurrence of CVS and DCI. Study population: adult patient admitted to ICU for aneurysmal SAH WFNS grade I-IV and mFisher 3-4. Intervention: Levosimendan (0.1 µg/kg/min) or placebo infusion at Day 1 and 8. Primary outcome: incidence of DCI or CVS at day 14 Duration of the study: 24 months Number of patients: 30 (15 patients per group) Number of center: 1

NCT ID: NCT05649904 Recruiting - Clinical trials for Subarachnoid Hemorrhage

AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis

AFFECT
Start date: February 7, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate efficacy and safety of evacuation of cerebrospinal fluid, blood, and harmful bacteria from the intraventricular, subdural and subarachnoid spaces by Active Controlled Irrigation and Drainage (IRRAflow) compared to Passive External Ventricular Drainage (EVD). Subjects with intraventricular hemorrhage, subarachnoid hemorrhage, subdural bleeding, and ventriculitis will be randomized to receive the IRRAflow device or EVD device and followed for one month post-procedure to compare outcomes between the subject groups.